Inovio Pharmaceuticals, Inc. (INO)
| Market Cap | 116.07M +141.8% |
| Revenue (ttm) | 65,343 -70.0% |
| Net Income | -84.95M |
| EPS | -1.81 |
| Shares Out | 69.09M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 619,934 |
| Open | 1.650 |
| Previous Close | 1.630 |
| Day's Range | 1.630 - 1.720 |
| 52-Week Range | 1.300 - 2.979 |
| Beta | 1.76 |
| Analysts | Buy |
| Price Target | 9.00 (+435.71%) |
| Earnings Date | Mar 12, 2026 |
About INO
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervi... [Read more]
Financial Performance
In 2025, Inovio Pharmaceuticals's revenue was $65,343, a decrease of -69.99% compared to the previous year's $217,756. Losses were -$84.95 million, -20.80% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for INO stock is "Buy." The 12-month stock price target is $9.0, which is an increase of 435.71% from the latest price.
News
Inovio Stock Up On Earnings, Pipeline Progress
Inovio Pharmaceuticals Inc (NASDAQ: INO) shares are trading higher on Friday morning after the company reported fourth-quarter results that topped Wall Street's loss estimate and highlighted progress ...
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U...
Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at The Citizens Life Sciences Conference 2026 Transcript
INOVIO to Participate in Upcoming Scientific Conferences
PLYMOUTH MEETING, Pa., March 9, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026
PLYMOUTH MEETING, Pa., March 5, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
Akeso and INOVIO Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Collaboration will evaluate Akeso's cadonilimab in combination with INOVIO's INO-5412 (INO-5401 plus INO-9012) as a potential treatment for glioblastoma (GBM), the most common and aggressive form of b...
INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM)
Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive form of b...
Inovio Pharmaceuticals, Inc. (INO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
INOVIO to Participate in Upcoming Scientific and Investor Conferences
PLYMOUTH MEETING, Pa., Feb. 12, 2026 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-asso...
Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107
I believe Inovio Pharmaceuticals' upside rests almost entirely on INO-3107. The FDA set a standard-review PDUFA for October 30, 2026. INO-3107 targets HPV-6/11 RRP, aiming to reduce repeat surgeries b...
FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
PLYMOUTH MEETING, Pa. , Dec. 29, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa. , Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re...
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Inovio Pharmaceuticals, Inc. (INO) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
INOVIO to Participate in December Investor Conferences
PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
Inovio 3Q25 Review: EPS Miss, $25M Offering, And INO-3107 Progress
Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash...
INOVIO Announces Pricing of $25 Million Public Offering
PLYMOUTH MEETING, Pa. , Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot...
Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript
Inovio Pharmaceuticals, Inc. ( INO) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jennie Willson Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical ...
INOVIO Announces Proposed Public Offering
PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and prot...
INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 ...
INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults
Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy designat...
INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025
PLYMOUTH MEETING, Pa. , Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-ass...
INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference
PLYMOUTH MEETING, Pa. , Oct. 23, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-as...
Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine
Publication includes complete data for all participants (n=39) up to week 72, further demonstrating durable and tolerable expression of DMAbs Effective target binding and confirmed functional activity...
Inovio Pharmaceuticals, Inc. (INO) Presents At H.C. Wainwright 27th Annual Global Investment Conference (Transcript)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) H.C. Wainwright 27th Annual Global Investment Conference September 5, 2025 7:00 AM EDT Company Participants Jacqueline Shea - CEO, President & Director Confe...